抵抗素样分子β在非小细胞肺癌中的表达及其与临床病理特征的关系  

Expression of RELMβ in non-small cell lung cancer and the its relationship with clinicopathological features

作　　者：吕叶[1,2] 茅卫东[2] 苏筠[2] 沈孝兵[3] 姜藻[1] 

机构地区：[1]东南大学附属中大医院肿瘤科,江苏南京210009 [2]东南大学附属江阴医院肿瘤科,江苏江阴214400 [3]东南大学公共卫生学院,江苏南京210009

出　　处：《南京医科大学学报（自然科学版）》2015年第6期823-826,共4页Journal of Nanjing Medical University(Natural Sciences)

基　　金：国家自然科学基金(81172619)

摘　　要：目的 :探讨抵抗素样分子β(resistin-like molecule beta,RELMβ)在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达及其与临床病理特征的关系。方法:应用逆转录-聚合酶链反应(RT-PCR)方法和蛋白免疫印迹检测103例NSCLC组织及癌旁正常肺组织(其中65例具有配对的淋巴结转移标本)中RELMβ的表达情况,分析其表达与临床病理特征之间的关系。结果:RT-PCR和蛋白免疫印迹结果均显示,RELMβ在NSCLC组织中的表达明显高于正常肺组织。RELMβm RNA在肺癌组织中的表达(68.93%)显著高于癌旁组织(23.33%,P<0.05)。不同肿瘤的分化程度、TNM分期及淋巴结转移情况,RELMβ的表达强度不同,差异有统计学意义(P<0.05)。结论:RELMβ在NSCLC组织中异常高表达,与肺癌临床病理学特征相关,可能促进NSCLC的恶性进程。Objective：This study aimed to detect the expression of resistin-like molecule beta（RELMβ）in human non-small cell lung cancer （NSCLC） and its relationship with clinicopathological characteristics. Methods： We detected the expression levels of RELMβ in 103 NSCLC tissues and the same patients＇ adjacent noncancerous tissues （including 65 with paired lymph node metastases） by reverse transcription polymerase chain reaction （RT-PCR） and Western blot, and then analyzed their correlation with clinical pathological parameters. Results： RT-PCR and Western blot showed that the expression level of RELMβ in NSCLC tissues was significantly higher than that in noncancerous tissues. Compared with adjacent noncancerous tissues, the mRNA and protein expression levels of RELMβ were significantly increased in lung cancer （23.33% ,P 〈 0.05）. The high expression of RELMβ was closely associated with the degree of differentiation, TNM staging and lymph node metastasis （P 〈 0.05）. Conclusion： The positive expression of RELMβ is associated with clinical pathological parameters of NSCLC. RELM β may promote tumor progression.

关 键 词：抵抗素样分子β 非小细胞肺癌 基因表达 

分 类 号：R734.2[医药卫生—肿瘤]